The second purchase is priced in the footnote, and it is the number that matters
Every price on this site is a prepaid block rather than a subscription, and the footnote says so directly: this is not a subscription service, you will be charged once for the selected plan, and no automatic billing or recurring charges will occur.
The same footnote then does something almost nothing else here does. It states what the next supply costs. That figure is more than twice the advertised per-month rate, and it is quoted per four weeks rather than per month.
So the honest reading of this site is that the advertised figure is an introductory block and the footnote is the real price. Publishing it at all is genuinely good practice. Publishing it inside the footnote of the thing it contradicts is why this row does not score for price stability.
The headline is a weekly figure, and we did not rank it as a monthly one
A banner runs across every page quoting a price per week. Multiply it by twelve and you get the one-time payment printed on the tirzepatide card exactly.
That is a legitimate way to describe a twelve-week prepayment, and the site does also print the monthly framing of the same plan. But a weekly number is not comparable to a monthly one, and storing it as a price row would have placed it among the three lowest figures on a roster of ninety-five monthly ones — a false comparison manufactured by us, not by the seller.
It sits in the tirzepatide row's qualifier instead, with the arithmetic shown, so a reader can see where it comes from without a board treating it as a month.
The compounded injection does not say what it is
The compounded product page is headed compounded GLP-1 and the copy says a clinician will help you find the right dose of a GLP-1 medication, such as compounded GLP-1. The molecule is never stated.
The word semaglutide appears twice on that page, both times inside a disclaimer explaining that two named brand drugs are approved products and not compounded preparations. That is a statement about the brands, not about the vial.
And the site's own navigation lists compounded GLP-1 and compounded tirzepatide as two separate products, so the unqualified one is not shorthand for the other. Twelve of the ninety-five sellers here withhold the molecule behind a figure in one form or another, and this is one of them.
Brand-name prices, quoted per month and defined as four weeks
Two brand products have their own pages with their own cash prices. Fifty of the ninety-five sellers here offer a brand route of some kind, and very few of them put a figure on it in public.
Both figures are labelled per month. Both footnotes define them as a paid-upfront order of a four-week plan. Four weeks is not a month: it is thirteen payments a year rather than twelve, and on figures this size the difference is not small.
Our record marks both rows as not monthly, so no template on this site can print a monthly suffix beside them. Fifteen of the ninety-five sellers here carry at least one figure that is not a monthly rate.
The privacy policy narrates its own rewriting
This is not a price finding and it is the strangest thing in this batch. The published privacy policy is written in the third person about a document it calls the source policy, which is not published: sentence after sentence begins with the words the source policy states that.
In one passage it stops describing and starts explaining. It says that to remove an age-related inconsistency, this rewrite states the policy in clearer form — and then gives the clearer form.
Whatever produced that document, what is published is a summary of an unpublished original, with its editorial reasoning left in. A privacy policy is a legal notice about what happens to your health data. This one is a commentary on a legal notice, and the notice itself is not on the site.
There is no terms of service to read at all: the path returns a not-found response with no content. No pharmacy is named, no clinician is named, and no state list exists on any of the six pages we read.
HeliMeds's published pricing
| Medication | Price | Verified |
|---|---|---|
| Glp-1 (compounded) | $99/mo"EasyStart - 3 months / SAVE $420 / $99/month", footnoted "*price with paid upfront first order of 12-week plan. This is not a subscription service. You will only be charged once for the selected treatment plan. No automatic billing or recurring charges will occur. Next 4-week supply orders $239.00." ⛔ THE SECOND PURCHASE IS PRICED IN THE FOOTNOTE AND IT IS $239 FOR FOUR WEEKS — more than twice this figure, and on a 4-week cycle rather than a month. | September 2026source |
| Glp-1 (compounded) | $199/moThe non-starter lane on the same card: "Any dose - 3 month / $199/month", under the same paid-upfront footnote and the same $239 per-4-week refill note. | September 2026source |
| Tirzepatide (compounded) | $149/mo"Compounded Tirzepatide 12-week supply / Starter Dose / $447 one time payment / SAVE $50 / $149/month". ⚠ THE SITE HEADLINES THE SAME PLAN PER WEEK ON EVERY PAGE — "Get GLP1+GIP for $37.25/week" — which is $447 ÷ 12 weeks. A weekly figure and a monthly figure for one prepayment; this row stores the monthly one the seller itself prints, and the weekly headline is recorded here rather than ranked as if it were a monthly rate. | September 2026source |
| Tirzepatide (compounded) | $232/mo"Any other dose / $697 one time payment / SAVE $50 / $232/month" on the same card. $697 ÷ 3 = $232.33. | September 2026source |
| Semaglutide (brand) | $1,599⛔ FOUR WEEKS, NOT A MONTH — thirteen payments a year, not twelve. "Wegovy® / SAVE $50 / $1599/month / *price with paid upfront order of 4-week plan. This is not a subscription service. You will only be charged once for the selected treatment plan." The seller labels the figure per month and its own footnote defines it as a 4-week plan; the label and the term do not agree, so this row does not print a monthly suffix. | September 2026source |
| Tirzepatide (brand) | $1,396⛔ FOUR WEEKS, NOT A MONTH. "Zepbound® / $1396/month / *price with paid upfront order of 4-week plan. This is not a subscription service. You will only be charged once for the selected treatment plan. No automatic billing or recurring charges will occur." Same label-versus-term mismatch as the Wegovy row. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 95 providers reviewed here are paid partners today; the other 91 are not. See how this works.
See HeliMeds's current price →Good fit if
- Readers comparing brand-name cash prices, who will convert a four-week figure to a year before treating it as monthly.
- Buyers who want to be told what the second purchase costs before making the first one.
- People who want a stated absence of subscriptions, automatic billing and recurring charges.
- Anyone who wants the one-time total printed beside the divided-down per-month figure.
Look elsewhere if
- Anyone budgeting from the advertised rate. The footnote under it prices the next supply at more than twice as much, per four weeks.
- Readers who need to know which molecule they are taking. The compounded injection is sold as a GLP-1 with no drug named.
- Buyers who want a terms-of-service document. The path returns a not-found response with no content.
- Anyone who wants a privacy policy rather than a third-person summary of an unpublished one.
- Readers who need a pharmacy, a clinician or a state list. None of the three appears anywhere.
How this review was verified
- Re-read the homepage, the compounded GLP-1 page, the compounded tirzepatide page, both brand pages and the privacy policy on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller.
- Compared the effective URL to the requested one on every fetch, which is how we found that the tirzepatide path returns a different page than the one requested. The source URL on that row is the path that actually serves the card.
- Checked the arithmetic on the weekly headline: the per-week figure times twelve equals the one-time payment printed on the card exactly. That is why it is recorded in the qualifier and not stored as a price row.
- Kept the weekly figure out of the price rows deliberately. Stored as a monthly row it would have sat among the three lowest figures on a roster built from monthly ones, which would be a false comparison introduced by this site rather than by the seller.
- Counted the molecule references on the compounded product page rather than assuming from the path: the word semaglutide appears twice, both inside a disclaimer about two brand drugs, and never as a statement of what is in the vial.
- Marked both brand rows as not monthly, on the seller's own footnote defining each as a four-week plan while labelling the figure per month.
- Requested the terms of service and recorded the result: a not-found response with zero characters of text. There is no terms document on this site to read.
- Read the privacy policy in full and quoted its self-narration rather than paraphrasing it.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a positive control and a nonsense-string negative control in the same run. Neither returned a letter; untitled letters are published separately and were not searched.